NOS3 and coronary artery disorder: As a novel therapeutic option for ischemic heart disease, we developed a low-intensity pulsed ultrasound (LIPUS) therapy that upregulates endogenous endothelial nitric oxide synthase (eNOS) with resultant angiogenesis and suppression of chronic inflammation [2, 3].